10x Genomics, which provides a single-cell sequencing platform for biomedical research, raised $390 million by offering 10 million shares at $39, above the upwardly revised range of $36 to $38. The company had originally filed to sell 9 million shares at a range of $31 to $35. At the IPO price, the company raised 18% more in proceeds than previously anticipated and commands a fully diluted market value of $4.2 billion.
10x Genomics plans to list on the Nasdaq under the symbol TXG. J.P. Morgan, Goldman Sachs and BofA Merrill Lynch acted as lead managers on the deal.
